Using the HDAC6-specific inhibitors, ACY-1215 and ACY-241, on T-cells from metastatic melanoma patients, the authors observed decreased cytokine production (IL-4, IL-5 and IL-6), decreased FOXP3 expression (a master regulator of regulatory T cells) and higher T-cell infiltration in melanoma upon treatment 139. This evidence concerns the gene HDAC6 and melanoma.